Geoffrey R Oxnard

基本信息

浏览量：257

职业迁徙

个人简介

The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.

研究兴趣

论文共 580 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Tumor Mutational Burden and Survival on Immune Checkpoint Inhibition in >8000 Patients Across 24 Cancer Types

David R Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel J Klempner,Miles C Andrews,Amit Mahipal, Vivek Subbiah,Ramez N Eskander,David P Carbone, Jonathan W Riess, Sarah Sammons,Jeremy Snider, Lilia Bouzit,Cheryl Cho-Phan, Megan Price,Gerald Li,Julia C F Quintanilha, Richard Sheng Poe Huang,Jeffrey S Ross, David Fabrizio,Geoffrey R Oxnard,Ryon P Graf

Journal for immunotherapy of cancerno. 2 (2025)

引用0浏览0WOS引用

Round-Robin Comparison of RET Rearrangement Detection in Ctdna: A Novel Method for Limited Clinical Samples

Cloud P Paweletz, Alison Urvalek, Minh Ha,Kavita Garg,Aimee Bence Lin,Anna M Szpurka, Anthony Sireci,Geoffrey R Oxnard,Pasi A Janne

Clinical cancer research an official journal of the American Association for Cancer Researchno. 12 (2025): 2406-2412

引用0浏览0WOS引用

Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, from the LIBRETTO-001 Phase I/II Trial

Oliver Gautschi,Keunchil Park,Benjamin J Solomon,Pascale Tomasini,Herbert H Loong,Filippo De Braud,Koichi Goto,Patrick Peterson,Scott Barker, Katherine Liming,Geoffrey R Oxnard,Bente Frimodt-Moller,Alexander Drilon

Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 15 (2025): 1758-1764

引用0浏览0WOS引用

Benefits of Combining Circulating Tumor DNA with Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study

JCO precision oncology (2025): e2400283-e2400283

引用0浏览0WOS引用

Ctdna Clearance As an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

Hillary S Andrews, Nevine Zariffa,Katherine K Nishimura, Stephanie H Choi,Shibing Deng, Megan Eisele,Carin R Espenschied, Emily M Goren, Minakshi Guha, Samuel Hong,Dilafruz Juraeva, Nicole Krämer, Li Liu,Jean-Francois Martini, Brittany A McKelvey,Geoffrey R Oxnard,Gary A Pestano,Lynne Poole,Adam Rosenthal, Anna M Szpurka,Diana Merino Vega, Christine Ward, Sameera R Wijayawardana,Antje Hoering, Mark D Stewart, Jeff D Allen

Clinical cancer research an official journal of the American Association for Cancer Researchno. 11 (2025): 2162-2172

引用0浏览0WOS引用

Efficacité Et Tolérance De L’olomorasib (LY3537982), Un Inhibiteur De KRAS G12C (g12ci) De Deuxième Génération, Combiné Au Pembrolizumab Chez Des Patients Atteints D’un CBNPC Avancé Avec Mutation KRAS G12C

A. Hollebecque,T.F. Burns, K. Dragnev, Y. Fujiwara, Y.R. Murciano-Goroff, D.H. Lee, T. Koyama, P. Cassier, A. Italiano,R.S. Heist, J.Y. Han, D. Deming, A. Spira, J. Sabari,M.J. Chisamore, A. Fink, A. Chen, M.D. Willard,G.R. Oxnard, N.R. Ammakkanavar

Revue des Maladies Respiratoires Actualités（2025）

引用0浏览0引用

ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practice